Having trouble accessing articles? Reset your cache.

Cardiome falls on oral vernakalant delay

Shares of Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) fell on Wednesday after the company said partner Merck & Co.

Read the full 180 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE